LONG-TERM FOLLOW-UP OF CARDIOVASCULAR RISK-FACTORS IN PATIENTS GIVEN CHEMOTHERAPY FOR DISSEMINATED NONSEMINOMATOUS TESTICULAR CANCER

被引:82
作者
GIETEMA, JA
SLEIJFER, DT
WILLEMSE, PHB
KOOPS, HS
VANITTERSUM, E
VERSCHUREN, WMM
KROMHOUT, D
SLUITER, WJ
MULDER, NH
DEVRIES, EGE
机构
[1] UNIV GRONINGEN HOSP, DEPT INTERNAL MED, DIV MED ONCOL, OOSTERSINGEL 59, 9713 EZ GRONINGEN, NETHERLANDS
[2] NATL INST PUBL HLTH & ENVIRONM PROTECT, BILTHOVEN, NETHERLANDS
关键词
TESTICULAR NEOPLASMS; CARDIOVASCULAR DISEASES; CISPLATIN; HYPERCHOLESTEROLEMIA;
D O I
10.7326/0003-4819-116-9-709
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
. Objective: To assess cardiovascular risk factors over time in patients who received chemotherapy for disseminated testicular cancer and were apparently cured. . Design: Cohort study. . Setting: Referral center. . Patients: Fifty-seven consecutive patients (median age, 28 years; range, 16 to 43 years) who received cisplatin-containing chemotherapy between 1978 and 1985. . Measurements: Serum cholesterol and high-density lipoprotein (HDL) levels, body mass index (BMI), blood pressure, kidney function, and hormonal status were monitored during follow-up after chemotherapy (median follow-up, 88 months; range, 56 to 143 months). The BMI and cholesterol values obtained 4 to 6 years after chemotherapy were compared with values from a sample of healthy, age-matched Dutch men; the cholesterol level was also compared with that of 31 patients treated with orchidectomy for stage I disease. . Results: The mean cholesterol level in patients at the start of chemotherapy was 3.96 +/- 0.98 mmol/L [153 +/- 38 mg/dL], increasing 4 to 6 years later to 6.12 +/- 1.20 mmol/L [237 +/- 46 mg/dL] (P < 0.001); 49 of 57 patients had an elevated low-density lipoprotein (LDL) cholesterol level (> 3.4 mmol/L [130 mg/dL]), with a mean level of 4.47 +/- 1.05 mmol/L [173 +/- 41 mg/dL]. Compared with a sample of healthy Dutch men, the chemotherapy group had an elevated cholesterol level (P < 0.05). At 4 to 6 years, the mean HDL cholesterol level was 0.76 +/- 0.18 mmol/L [29 +/- 7 mg/dL], which was low compared with that of the healthy Dutch men (P < 0.05). The mean BMI for all patients was 2.8% higher than expected 4 to 6 years after chemotherapy (P < 0.01) but was not higher than expected 7 to 10 years after chemotherapy. . Conclusions: In addition to other known late side effects of chemotherapy in patients with testicular cancer, hypercholesterolemia and overweight might represent risk factors for cardiovascular disease in such patients, especially in those who are younger.
引用
收藏
页码:709 / 715
页数:7
相关论文
共 38 条
[21]  
2-8
[22]  
MILLER SR, 1981, JNCI-J NATL CANCER I, V67, P297
[23]  
NYDEGGER UE, 1972, CANCER RES, V32, P1756
[24]   ELEVATED SERUM-LIPIDS IN HYPOGONADAL MEN WITH AND WITHOUT HYPERPROLACTINEMIA [J].
OPPENHEIM, DS ;
GREENSPAN, SL ;
ZERVAS, NT ;
SCHOENFELD, DA ;
KLIBANSKI, A .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (04) :288-292
[25]  
ROOKUS MA, 1987, HUM BIOL, V59, P599
[26]   CISPLATIN-BASED COMBINATION CHEMOTHERAPY FOR DISSEMINATED GERM-CELL TUMORS - LONG-TERM FOLLOW-UP [J].
ROTH, BJ ;
GREIST, A ;
KUBILIS, PS ;
WILLIAMS, SD ;
EINHORN, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (08) :1239-1247
[27]   VASCULAR TOXICITY FOLLOWING VINBLASTINE, BLEOMYCIN, AND CISPLATIN THERAPY FOR GERM-CELL TUMORS [J].
SAMUELS, BL ;
VOGELZANG, NJ ;
KENNEDY, BJ .
INTERNATIONAL JOURNAL OF ANDROLOGY, 1987, 10 (01) :363-369
[28]  
SAMUELS BL, 1987, CANCER CHEMOTH PHARM, V19, P253
[29]   BODY-COMPOSITION, NOT BODY-WEIGHT, IS RELATED TO CARDIOVASCULAR-DISEASE RISK-FACTORS AND SEX-HORMONE LEVELS IN MEN [J].
SEGAL, KR ;
DUNAIF, A ;
GUTIN, B ;
ALBU, J ;
NYMAN, A ;
PISUNYER, FX .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 80 (04) :1050-1055
[30]   10-YEAR SURVIVAL AND LATE SEQUELAE IN TESTICULAR CANCER-PATIENTS TREATED WITH CISPLATIN, VINBLASTINE, AND BLEOMYCIN [J].
STOTER, G ;
KOOPMAN, A ;
VENDRIK, CPJ ;
STRUYVENBERG, A ;
SLEYFER, DT ;
WILLEMSE, PHB ;
KOOPS, HS ;
VANOOSTEROM, AT ;
HUININK, WWT ;
PINEDO, HM .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (08) :1099-1104